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Connexin32

and X-linked Charcot-Marie-Tooth

Disease

K . H . FISCHBECK, S . M . DESCHENES, L . J . BONE, AND S . S . SCHERER

Neurology Department, University of Pennsylvania School of Medicine,
Philadelphia, Pennsylvania 19104

A common theme in the Symposium is that the
identification of defective genes in hereditary neurological disease can give new insight into basic mechanisms of cellular structure and function. This paper
deals with the genetic defect responsible for the Xlinked form of Charcot-Marie-Tooth disease.
X-LINKED CHARCOT-MARIE-TOOTH DISEASE
AND CONNEXIN32
Charcot-Marie-Tooth disease (CMT) causes progressive weakness, atrophy, and sensory loss in the
feet, lower legs, and hands. Overall, CMT is a relatively common hereditary disorder, affecting about 1 in
2500 individuals, more than 100,000 Americans. The
cause of the manifestations of CMT is degeneration
of the peripheral nerves. In different families, the
degenerative process can affect the axons, the myelin,
or both.
CMT is genetically heterogeneous. It is classified
first according to whether the pathology is primarily
demyelinative or axonal, and second according to the
specific genetic defect (Chance and Fischbeck 1994).
The most common form, CMT1A, and a less common
form, CMT1B, are caused by defects in the genes for
myelin proteins PMP22 and P0, respectively. The Xlinked form of the disease (CMTX) is caused by mutations in the gap junction protein, connexin32 (Bergoffenetal. 1993b).
CMTX accounts for about 10% of patients with
CMT and is probably the second most common cause
of hereditary neuropathy after CMT1A. It is most
often considered an X-linked dominant disease (Fischbeck et al. 1990; Deschenes et al. 1996). The disease is
commonly passed from generation to generation, affecting both males and females as with autosomal dominant transmission, except that there is no father-to-son
transmission. Heterozygous females are variably involved and in some families may be asymptomatic.
Nerve conduction velocities tend to be slow, in an intermediate range, and nerve biopsies may show signs
of both demyelination and axonal degeneration.
Several years ago, we and other workers set out to
identify the CMTX disease gene by positional cloning,
and the disease locus was eventually narrowed to a
small segment of the proximal long arm of the X
chromosome, at Xql3.1 (Bergoffen et al. 1993a). The
interval to which CMTX was mapped contained three
previously identified genes, including the gene for con-

nexin32. We evaluated connexin32 as a candidate gene,
first by determining whether or not it is expressed in
peripheral nerve. Northern blots show that connexin32
is expressed in peripheral nerve, and that it follows the
same pattern of expression as other myelin-related
genes, decreasing in nerve that is degenerating after
transection and increasing in nerve that is regenerating
after a crush (Scherer et al. 1995). This pattern differs
from that of nerve growth factor receptor and the
housekeeping gene glyceraldehyde phosphate dehydrogenase. In cultured Schwann cells, connexin32 is expressed with other myelin genes when the cells are
treated with forskolin, an agent that increases cAMP
levels.
Connexin32 is encoded by a relatively simple gene
with two promoters, and the translated sequence is
contained in a single exon (Fig. 1). The first promoter,
PI, drives expression in the liver, where connexin32
was first identified, and elsewhere in the body. The second promoter, P2, is nervous-system-specific and
drives expression in peripheral nerve in a pattern
similar to other myelin genes. Once we knew that the
connexin32 gene is expressed in peripheral nerve and
mapped to the same location as CMTX on the X
chromosome, we set out to look for mutations in
CMTX patients. We found that the large majority of
CMTX patients have mutations in the translated portion of the gene (Bone et al. 1995). Since 1993, over 70
different mutations have been identified.
Many of the known CMTX mutations are shown in
Figure 2, where connexin32 is shown in its likely topographic orientation, as an integral membrane protein
with four transmembrane domains and amino and carboxyl termini within the cell. There are two extracellular loops with highly conserved cysteine
residues that are thought to be involved in intramolecular disulfide bonds that ultimately stabilize
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Figure 1. Structure of the human connexin32 gene. (ORF)
Open reading frame.
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Figure 2. Diagram showing the topographic orientation of connexin32 with the locations of known CMTX mutations. 74 different
mutations have been identified in 91 families.

the gap junction structure. The transmembrane
domains are also highly conserved across species and
among different members of the connexin gene family.
The CMTX mutations are mostly missense (amino acid
substitutions), although deletions, frameshifts, and
premature stop mutations are also seen. Mutations
have been found in every portion of the protein.

CONNEXIN32 STRUCTURE AND FUNCTION
Connexin32, like other members of the connexin
family, is a channel protein. Six identical subunits
cluster in the plasma membrane to form a hemichannel
or connexon. This structure docks with a similar structure in another membrane to form a complete channel.

CONNEXIN32 AND CMTX
The channel has a central pore that allows passage of
ions and other small molecules up to 1000 daltons in
size from one cell to another. An array of individual
channels makes up a gap junction.
Connexin32 is found in a variety of cells and tissues,
including liver, secretory epithelium, and brain. Until it
was implicated in CMTX, connexin32 was not known
to be expressed in peripheral nerve, nor were gap junctions known to play a role in peripheral nerve structure
and function.
What effect do the CMTX mutations have on the
function of connexin32? Roberto Bruzzone in David
Paul's laboratory at Harvard addressed this question
by introducing wild-type and mutant connexin32 into
Xenopus oocytes and assaying the formation of gap
junctions electrophysiologically (Bruzzone et al. 1994).
Normal connexin32, but not mutant connexin32, forms
functional gap junctions in this system. Furthermore,
mutant connexin32 interferes with the formation of
gap junctions by co-injected wild-type cDNA, suggesting a dominant-negative effect.
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Figure 4. Teased fiber preparation of rat sciatic nerve, showing immunofluorescent staining of connexin32 at nodes of
Ranvier and Schmidt-Lanterman incisures.

INTRACELLULAR TRAFFICKING OF MUTANT
CONNEXIN32
We have gone on to investigate the fate of mutant
connexin32 in stably transfected mammalian (PC12J)

Figure 3. Immunofluorescence of connexin32 in stably transfected PC12J cells. (A) Wild-type connexin32, which localizes
to the plasma membrane at points of cell-cell contact. (B)
Mutant connexin32, which remains in the cytoplasm.

cells. Here the wild-type connexin32 protein forms aggregates at points of cell-cell contact (Fig. 3A). These
are not seen in nontransfected cells. Immunohistochemistry of cells transfected with connexin32 cDNA
derived from a CMTX patient shows that the mutant
protein "hangs up" in the cytoplasm, most prominently
in the endoplasmic reticulum and Golgi apparatus, and
is not properly routed to the plasma membrane (Fig.
3B).

Figure 5. Confocal image of myelinated nerve fibers showing
immunofluorescent staining of PQ (green) and connexin32
(orange).
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Figure 6. Schematic diagram of myelinated nerve, with the Schwann cell "unwound." Shown are the relative distributions of connexin32 and other myelin proteins and the location of putative gap junctions.

We have looked at seven different mutations and
have found different effects on intracellular trafficking.
In one case, the mutant cDNA is expressed at the
mRNA but not the protein level; perhaps this protein
is degraded too rapidly to give signal by immunofluorescence and Western blot. In several cases, some
plasma membrane signal is seen. However, with most
mutations, particularly those affecting residues within
and adjacent to the transmembrane domains, the protein accumulates in the cytoplasm. It may be that misrouted connexin32 protein has a toxic effect on
Schwann cells and axons, beyond the direct effects of
loss of the protein's function. We plan to sort out toxic
or dominant-negative effects in vivo by studying transgenic mice.
We are using transgenic constructs with the P0
promoter to introduce two different mutant forms of
connexin32 into mice. These mice are being bred with
connexin32 knockout mice to observe the effects of the
mutations on a null background. The knockout mice
were produced by Dr. Klaus Willecke in Bonn, and
have a relatively mild phenotype, consistent with a
dominant-negative or toxic effect of the mutant protein
on peripheral nerve.

CONNEXIN32 FUNCTION IN NORMAL NERVE
What is connexin32 doing in peripheral nerve? We
can begin to answer that question by looking to see
where connexin32 is normally located. We have done
immunohistochemistry and have found connexin32 to
be present in noncompacted myelin around the nodes
of Ranvier and at Schmidt-Lanterman incisures
(Bergoffen et al. 1993b; Scherer et al. 1995). This is a
different distribution from other proteins implicated in
hereditary neuropathy, PMP22 and P0, which are lo-

cated in compact myelin. The incisures and paranodes
where connexin32 is located are residual folds of noncompacted Schwann cell cytoplasm that remain after
the Schwann cell wraps itself around the axon to form
the myelin sheath.
Figure 4 shows a teased fiber preparation demonstrating connexin32 staining in noncompacted myelin
at the nodes and incisures. Figure 5 is a confocal image
of myelinated nerve fibers with P0 stained green in the
compact myelin, and connexin32 stained orange at the
node of Ranvier. There is no overlap between the distributions of P0 and connexin32. Figure 6 shows the
locations of connexin32 and other myelin proteins in
peripheral nerve. David Paul proposed that connexin32 forms "reflexive" gap junctions at these sites,
connecting different parts of the same Schwann cell
rather than two different cells, and forming a path for
diffusion of ions and other small molecules across the
myelin sheath. This path perhaps provides nutritional
support to the innermost layers of Schwann cell cytoplasm and indirectly to the axon, as well.
Preliminary results with injection of different dyes
into myelinating Schwann cells of peripheral nerve indicate that such a path does indeed exist (R. BaliceGordon et al., unpubl.). Low-molecular-weight dyes
pass rapidly through incisures to the inner layers of
Schwann cell cytoplasm, whereas high-molecularweight dyes do not. We suspect that a loss of this pathway and perhaps additional toxic effects of misrouted
protein account for the myelin loss and axonal degeneration of X-linked Charcot-Marie-Tooth disease.
The connexin32-CMTX story demonstrates how,
when the interests of basic research and clinical medicine are coincident, we are brought to a better understanding not only of disease mechanisms, but also of
the essentials of normal nervous system structure and
function.

CONNEXIN32 AND CMTX
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